Ratings KOLMAR BNH Co.,Ltd.

Equities

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
15,670 ^KRW	+1.23%		+3.98%	-12.65%

Mar. 18	KOLMAR BNH Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Kolmar BNH Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The company's attractive earnings multiples are brought to light by a P/E ratio at 10.27 for the current year.
The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
The company appears to be poorly valued given its net asset value.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The valuation of the company is particularly high given the cash flows generated by its activity.
For the past year, analysts have significantly revised downwards their profit estimates.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
KOLMAR BNH CO.,LTD.	-12.65%	326M		-
ZHEJIANG NHU COMPANY LTD.	+4.07%	7.38B		D+
BELLRING BRANDS, INC.	-2.16%	7.1B		C-
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	-2.13%	5.88B		-
BYHEALTH CO., LTD	-3.82%	3.86B		D
THE SIMPLY GOOD FOODS COMPANY	-16.24%	3.24B		B-
XIAMEN KINGDOMWAY GROUP COMPANY	-17.39%	1.12B	-	-
SIRIO PHARMA CO., LTD.	+5.02%	894M		-
USANA HEALTH SCIENCES, INC.	-17.67%	836M		C+
JAMIESON WELLNESS INC.	-17.55%	790M		C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality